NAVIGATIONINFORMATION REQUEST |
Michael A. Singer, M.D.
FACULTY University of Texas Health Science Center San Antonio, TX Dulaney Foundation, Continuing Medical Education The Management of Recurrent Macular Edema in Retina Disease APPOINTMENTS Clinical Assistant Professor 2004-Present Developed Retina Research Program 2009-2011 Methodist Ambulatory Surgical Hospital San Antonio, TX Chairman of Ophthalmology 1999 - Present University of Southern California Los Angeles, CA Clinical Faculty 1998-2000
EDUCATION Boston University School of Medicine Boston, MA Six-Year Medical Program May 18, 1986 Doctor of Medicine: Medical Degree Bachelor of Arts May 18, 1986
POST GRADUATE MEDICAL TRAINING
Fellowship Eye Consultants of Atlanta Atlanta, GA Piedmont Hospital July 1, 1991-June 30, 1992 William Hagler, MD and William Jarrett, MD Retina Fellowship
Residency St. Vincent’s Hospital and New York, NY Medical Center of New York July 1, 1988-June 30, 1990 Ophthalmology Resident
Ophthalmology Chief Resident July 1, 1990-June 30, 1991
Pre-Residency Doheny Eye Institute Los Angeles, CA Pre-Residency Fellowship 1987-1988 Internship LA County USC Medical Center Los Angeles, CA Ophthalmology Internship June 24, 1986-June 27, 1987
CERTIFICATIONS
Board American Board of Ophthalmology October 18, 1992 Certification Re-certification December 31, 2002
PRK Certifications Summit UCLA January 1996 VISX (USC) June 1996
SOCIETIES AND BOARDS
Ophthalmology American Academy of Ophthalmology, Fellow 1993 Future Focus: “Transitioning to Managed Care” October 29, 1994 Expert Panel Member San Antonio Society of Ophthalmology 1996-Present American Society of Retina Specialists 1995-Present
Retina Society 2010-Present
Primary investigator of Record to FDA Horizon Study for wet macular degeneration 2010 Sirius Study (SIRNA for Age Related Macular Degeneration) Allergan 2009
AWARDS Kaiser Permanente - Physician Innovation Award 1994 American Society of Retina Specialists Honor Award 2006 American Society of Retina Specialist 2009 Senior Honor Award - New York, NY American Society of Retina Specialist Film 2009 Festival Award - New York, NY
Advisory Boards Neovista Medical Advisory Board May 2011-Present
Independent safety Monitoring Committee Quintiles Stem Cell Study: Protocol No. CNTO2476MDG1002: Phase 1/2a, Multicenter, Randomized, Dose Escalation, Fellow-Eye Controlled, Study Evaluating the Safety and Clinical Response of a Single, Subretinal Administration of Human Umbilical Tissue-Derived Cells (CNTO 2476) in Subjects with Visual Acuity Impairment Associated with Geographic Atrophy Secondary to Age-related Macular Degeneration 2010-Present Genentech Publication Advisory Board 2008, 2009, 2010 DRCRnet Protocol R Design Committee September 2009-Present Advisor for Brimonidine Retinal Detachment Study 2009 ISTA Pharmaceuticals Global Advisory Board 2005-2006 Allergan Global Advisory Board 2007-2011 Genentech Global Advisory Board 2008-2010 Macusight Emerald Study Advisory Board 2009-2010 Journal Reviewer Ophthalmology 2011 Retina 2011 PUBLICATIONS (Peer Reviewed) Submitted Singer, MA , Awh, CC, Sadda,SV, Freeman,WR, Antoszyk,AN, Wong, P, Tuomi, L. HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Submitted to Ophthalmology July 2011
Singer, MA , Bell,DJ, Woods, P. Effects of combination therapy with Bevacizumab and Dexamethasone intravitreal implant in patients with Retinal Vein Occlusion-Six month results. Submitted to Retina May 2011. Singer MA. Long Term Safety of Non-steroidal Anti-Inflammatory Drops. Submitted to Ophthalmology 2011.
Accepted
Singer, MA , del Cid, MR, Stelton, CR, Boord, T. Pars Plana Posterior Capsulotomy in a Patient with a Telescope Prosthesis for Age-Related Macular Degeneration. Archives of Ophthalmology (Manuscript EST05004), August 2010, Vol 128 (No 8).
Shields, C, Piccone, M, Shields, J, Eagle, R, Singer, MA . Mushroom-shaped Choridal Recurrence of Retinoblastoma-25 Years After Therapy. Archives of Ophthalmology Vol. 120, June 2002.
Singer, MA , Botulinum, T. Treatment of Essential Blepharospasm and Heminfacial Spasm. Ophthalmology Vol 3, 3 pg 48, September 1996.
Singer, MA , Hagler, WS, Grossniklaus, HE. Toxoplasmosa Gondii Retinochoroiditis After Liver Transplantation Retina Vol 13 (Issue No 1) pg 40-45, 1993
(Not Peer Reviewed) Singer, MA . Age-Related Macular Degeneration San Antonio Medicine, Volume 56 Number 3, March 2003.
Singer, MA . Benefits of Spectral Domain OCT in Refractive Eyecare June (2009)
Reporter for Retina Times. ASRS meeting 2009-2011
Singer, MA . Retinal Vein Occlusions: Transferring Studies into Clinical Practice. Retina Times, October 2010. Singer MA . Doctor-patient Relations in the Treatment of RVO. Retina today, June 2011.
Practice. Retina&vitreo, June 2011.
Singer MA. Developing Effective Steroid/Anti-VEGF Combination Therapy Regimens. Retina Physician, May 2011. Singer MA. Combination Therapy. Retina Today. September 2011.
Podcasts Retina Today Video Podcast, Eyetube Radio, Dr. David Boyer speaks with Dr. Michael Singer of Medical Center Ophthalmology Associates in San Antonio, TX, September 2011
Retina Today Podcast, Eyetube Radio, Dr. David Brown speaks with Dr. Michael Singer of Medical Center Ophthalmology Associates in San Antonio, TX, July 2011
Singer MA , Oetting T. MOC Exam Review Course: "The Academy's best kept ecret." American Academy of Ophthalmology Podcast, June 2011.
Videos Eyetube Video, Ozurdex Pearls and Pitfalls, September 2009 Eyetube Video, Biopsy of Retinal Lesions with a Novel Sub-Retinal Aspiration Cannula, October 2009 Non-Ophthalmology Boards Kaiser Permanente Management Association 1994-1995 Board of Directors American Diabetes Association, President July 1996-July 1998 Humana Utilization Review Board 1996-2003 Champus Utilization Review Board 1996-2003 Juvenile Diabetes Foundation, Board Member September 1999- September 2002 Socrates Social Venture Fund Aspen, CO Director of Scholarship Section December 2000-2003 Board Member 2003-2007 Board Member Acumen Fund Health Technology 2001-2008 Scientific Advisory Board MDTV Advisory Board 2002-2009 CAMP Independence for Diabetic Children (Faculty) 1996-Present CAMP Independence (Board of Directors) 2003-2009
Other Industries Dolce Food Corporation, Founder and CEO January 2004-January 2007 Founded Ice Cream Corporation – Created a sugar free product, distributed through 1,000 supermarkets in the southern U.S. Profits donated to diabetic education and research Board Member 2007-2010
Course Faculty Putting Research into Practice, Pravin Dugel Moderator 2010, 2011 Senior Posurdex Instructor for 012 (San Antonio, TX) 2007 Senior Posurdex Instructor for 016 (Boulder, CO) 2007 Senior Posurdex Instructor American Society 2008 of Retina Specialists (Palm Springs, CA)
PRESENTATIONS Singer MA, Bevacizumab and Dexamethasone intravitreal implant in patients with Retinal Vein Occlusion-Twelve Month Extention Study. Paper American Society of Retina Specialists, to be presented at Subspecialty Day, American Academy of Ophthalmology (Orlando, Fl. October 2011)
Singer MA , Patel SS, Uy HS, Liu C-C, Li X-Y, Li SM. Dexamethasone Intravitreal Implant (DEX Implant) Alone and as an Adjunct to Ranibizumab for the Treatment of Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (ARVO 2011) Poster Paper Retina Society 2011. American Society of Retina Specialists 2011.
Singer MA , Bell, DJ, Boord, T. Effects of combination therapy with Bevacizumab and Dexamethasone intravitreal implant in patients with Retinal Vein Occlusion-Six month results. American Society of Retina Specialists (Vancouver,Canada, 2010), Subspecialty Day, American Academy of Ophthalmology (Chicago, IL, 2010) Paper/Poster
Singer MA , Gupta S, Ciulla T, Liu C-C, Lou J, L X-Y. Safety and efficacy of intravitreal Dexamethasone implant plus laser photocoagulation versus laser alone for treatment of diffuse Diabetic Macular Edema. Retina Society (San Francisco, CA, 2010) Paper
Singer, MA , Gray S, Murahashi W Yee, Saroj,N, Rundle, A, Rubio, R Subgroup Analyses of Visual Acuity Outcomes in the BRAVO Study of Intravitreal Ranibizumab in Patients with Macular Edema Following Branch Vein Occlusion, Association of Research and Vision in Ophthalmology 2010. Poster
Kuppermann, B, Singer, MA , Tufail, A, Lou, J, Li, Xiao-Yan, Whitcup, S. Ozurdex TM (Dexamethasone Intravitreal Implant) as Adjunctive Therapy to Lucentis® in Patients with Chroroidal Neovascularization Secondary to Age-Related Macular. Association of Research and Vision in Ophthalmology 2010. Paper
Del
Cid MR, Singer MA . Corneal Melts Associated with
the Use of Topical Nonsteroidal Anti-Inflammatory Drugs (NSAIDs):
A Review of the Literature. Alamo City Ophthalmology Clinical Conference,
San Antonio, TX, 2010.
Singer, MA , Bell, DJ, Boyer, D. et al. Non-Steroidal Drops Safe for Long-Term Use? American Academy of Ophthalmology, poster presentation San Francisco, CA, October 2009.
Singer, MA , Bell, DJ, Boord, T. Effect of Combination Therapy with Bevacizumab and Dexamethasone Intravitreal Implant in Patients with Retinal Vein Occlusion. Vindico Medical Education, Maui, HA, January 2010. Presentation
Singer, MA , del Cid, MR., Bell, DJ., Trichopoulos, N, O’Conner, P, Padmanabhan, S. Unknown Case presented at the Imaging Conference at the Retina Congress as well as submitted at the film festival (2009)
Singer, MA , Wong, P, Tuomi, L. Visual Acuity after 2 Years in the Horizon Trail of PRN Intravitreal Ranibizumab (Lucentis) in Patients with Neovascular Age-related Macular Degeneration presented at the Retina Congress, New York, NY (2009) Poster
Singer, MA , Wong, P, Tuomi, L. Visual Acuity after 2 Years Data for Safety and Efficacy in the Horizon Trail of PRN Intravitreal Ranibizumab ( Lucentis® ) in Patients with Neovascular Age-related Macular Degeneration presented at the ARVO (2009) (submitted for publication) Paper
Singer, MA , Wong, RL, Rodriguez, J, Alderete, C, Johnson, S. Like Reaction After Oral Moxifloxacin (Avelox) Administration Presented at American Society of Retina Specialist 25 th Annual Meeting. Palm Springs, California, December 1-5, 2007. Poster
Singer, MA , Wong, RL; Alderete, C, Hartman, R. Vitrase for Vitreous Hemorrhage Revisited Presented at The Cannes Retina Festival Nice, France, September 9-13, 2006. Paper
Singer, MA , Wong, RL, Alderete, C, Hartman, R. Avastin – It’s Not Just For Retina Anymore. Poster at the Cannes Retina Festival Nice, France; 9-13 September 2006. Poster
Singer, MA , Fisher, SJ, Hartman, R. Surgical Capsulotomy in an Implantable Miniature Telescope Patient Presented at the American Society of Retina Specialists Montreal, Quebec, Canada, July 16-20 2005. Poster Singer, MA , Kimbrell, PN Comparison of Central Retinal Artery Occlusion in Eyes With and Without Hyperbaric Oxygen Presented at the American Society of Retina Specialists Montreal, Quebec, Canada, July 16-20, 2005. Paper
Singer, MA , Cohen, JH, Scribbick, F, Garcia, IM, Paulson, C. Increases in Intraocular Pressure after Kenalog Injection Presented at the American Society of Retina Specialists Annual Meeting New York, New York; August 2003. Paper
Warman, JR, Crawford, J, Evans, RM, Simmons, JW, Stanley, EA, Strohlow, R, Singer, MA . Dependency-Induced Increase in Intraocular Pressure: A Contributing Factor for Postoperative Visual Loss After Spinal Surgery Poster Exhibit Presented at the Scoliosis Research Society Annual Meeting Seattle, Washington; September 2002. Paper
Shields, C, Piccone, M, Shields, J, Eagle, R, Singer, MA . Mushroom-shaped Choridal Recurrence of Retinoblastoma-25 Years After Therapy. Archives of Ophthalmology Vol. 120, June 2002.
Singer, MA . Transthermotherapy in the Treatment of Classic and Occult Choroidal Neovascularization. Presented at the IRIS Pre-Academy Meeting October 2000; 2001 Vitreous Society Meeting; and “Expert Speaker” Iridex Booth American Academy of Ophthalmology 2001. Paper
Singer, MA , Levy, G. The Evidence of Plaquenil Retinopathy in a Large Multi-Center Outpatient Practice. Presented at American Academy of Ophthalmology Meeting October 1995. Poster
Singer, MA , Kowalski, G. The use of EMLA to Reduce Pain of Botulinum Toxin Injections Presented at Blepharospasm Foundation Conference, September 1995. Paper
Singer MA , Rio, N. The Pathologic Effects of Retained Perflourocarbons Presented at the Vitreous Society August 1994. Poster
Singer MA , Schwatz, SD, Green, RL, et al. Factors Associated with Retinal Detachment in Penetrating Ocular Trauma. Investigative Science; 1988 (29): 303 Presented as a poster ARVO 1988, Sarasota, Florida
Gaster, R, Burstein, N, Singer, M.A . Laser Surgery of the Cornea. Investigative Ophthalmology and Visual Sciences; 1987 (14); 45. Presented as a paper ARVO, Sarasota, Florida (1987)
Singer, M.A ; Wong, E.; Yaplee, S. The Presentation of a Lost Contact Lens, (Letter) CLAO, 1986 Oct-Dec (4) p. 200-201, presented at CLAO meeting, Las Vegas, Nevada, 1986 (poster)
RESEARCH Principal Investigator June 2002-July 2005 A Randomized, Placebo-Controlled, Double Masked, Multi-Center, Phase III Study of the Effect of Visudyne Therapy in Occult with No Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (QLT, Inc.)
Principal Investigator (Retina) January 2003-July 2005 A Prospective, Multi-Center Clinical Trial of the Implantable Miniature Telescope (IMT) in Patients with Central Vision Impairment Associated with Age Related Macular Degeneration (VisionCare) Principal Investigator May 2003-December 2005 A Phase III, Multi-Center , Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Rhufab V2 (Ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration (Genentech)
Principal Investigator August 2003-February 2006 A Phase III, Multi-Center , Randomized, Double-Masked, Active Treatment–Controlled Study of the Efficacy and Safety of Rhufab V2 (Ranibizumab) Compared to Verteporfin (Visudyne) Photodynamic Therapy in Subjects with Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration (Genetech)
Principal Investigator April 2004-September 2005 A Phase II Prospective, Randomized, Double Masked, Sham-Controlled, Dose Ranging, Multi-Center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients with Exudative, Subfoveal, Age-Related Macular Degeneration (Eyetech)
Principal Investigator June 2005-December 2007 A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficiency of Intravitreous Injections of 0.3µg Pegaptanib Sodium (Macugen ®), Given as Every 6 Weeks for 2 Years, to Sham Injections in Subjects with Diabetic Macular Edema (DME) Involving the Center of the Macula (Pfizer)
Principal Investigator April 2004-2008 A Randomized, Single-Masked, Multi-Center, Phase 2 Evaluation of the Effect of Photodynamic Therapy Using Verteporfin (Visudyne Therapy) In Combination with Intravitreal Injection of Either 0 mg, 1 mg, or 4 mg of Kenalog in Occult Subfoveal and Minimally Classic Subfoveal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (Novartis, QLT Inc.)
Principal Investigator April 2004-2008 A Six Month Phase 3, Multi-Center, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion (Allergan)
Principal Investigator January 2005-Current A 3-Year, Phase III, Multi-Center, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema (Allergan)
Principal Investigator June 2005-2008 An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (Genentech HORIZON AMD)
Principal Investigator November 2005-2007 A Phase IIIB, Single-Masked, Multi-Center, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naive and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (Genentech ANCHOR)
Principal Investigator May 2006-2008 A Phase II, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administrative of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration (Regeneron CLEAR)
Principal Investigator October 2006-2008 A 2-year, Multi-Center, Randomized, Controlled, Masked, Dose-Finding Trial to Assess the Safety and Efficacy of Multiple Intravitreal Injections of AGN211745 in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Allergan 016)
Principal Investigator May 2007- 2010 A 52-Week, Masked, Multi-Center, Randomized, Controlled Trial (with Up to 13 Weeks Additional Follow-Up) to Assess the Safety and Efficacy of 700mg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects with Diffuse Diabetic Macular Edema (DME) (Allergan 012)
Principal Investigator March 2007-2010 A Phase III, Multi-Center, Randomized, Sham injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion (Genentech BRAVO)
Principal Investigator March 2007-2010 A Phase III, Multi-Center, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (Genentech CRUISE)
Principal Investigator April 2007- Current A Randomized, Prospective, Active Controlled, Study of the Epi-Rad 90 ™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneration (NeoVista Cabernet)
Principal Investigator May 2007-Current A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration (Regeneron VIEW1)
Principal Investigator July 2007-2009 A 6-Month, Single-Masked, Multi-Center, Randomized, Controlled Study to Assess the Safety and Efficacy of 700mg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive therapy to Lucentis® Compared with Lucentis® Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Allergan 016)
Principal Investigator April 2007 -Current A Phase III, Double-Masked, Multi-Center, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus (Genentech RISE)
Principal Investigator August 2007-Current An Open-Label, Long-Term, Safety, and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration (Regeneron, 0702)
Principal Investigator May 2008 -Current A Multi-Center, Masked, Randomized, Sham-controlled, Paired-Eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Brimonidine Tartrate Postior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Patients with Geographic Atrophy From Age-related Macular Degeneration (Allergan 032D)
Principal Investigator August 2008 -Current A Multi-Center, Masked, Randomized, Sham-Controlled, Parallel-Group, 6-Month (Plus 6-Month Extension) Study to Evaluate the Safety and Effects on Visual Function of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Patients with Primary Open-Angle Glaucoma (Allergan, 030D)
Principal Investigator 2008-2010 A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy (MacuSight, Diamond)
Principal Investigator 2008-2010 A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis® Plus Sirolimus Versus Lucentis® Plus Placebo in Patients With Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (MacuSight, Emerald)
Principal Investigator May 2008- Current A Feasibility Study to Evaluate the Safety and Tolerability of the Epi-Rad 90 TM Ophthalmologic System for the Treatment of Subfoveal Chroidal Neoascularization (CNV) in Patients with Age-Related Macular Degeneration (AMD) That Have Failed Primary Anti-VEGF Therapy (NeoVista, Rose)
Principal Investigator April 2008-Current A Randomized, Single Masked, Long-Term, Safety, and Tolerability Study of Intravitreal VEGF Trap Eye in Subjects with Neovascular VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration (Regeneron VGFT-OD-0702)
Principal Investigator 2008-Current An Open-Label, Multi-Center Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech-Sponsored Ranibizumab Study (Genentech Horizon RVO)
Principal Investigator 2008-2010 A 26-Week, Open-Label Study to Assess the Safety and Efficacy of 700 m g Dexamethasone Posterior Segment Drug Delivery System Applicator System in the Treatment of Vitrectomized Subjects with Diabetic Macular Edema (DME) (Allergan 018)
Principal Investigator 2008-Current A 26 Week, Open-Label Study to Assess the Safety and Efficacy of 700 m g Dexamethasone Posterior Segment Drug Delivery System Applicator System In Conjunction with Lucentis â in the Treatment of Patients with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (Allergan 019)
Principal Investigator 2008-Current A Randomized,Placebo Controlled, Double-Masked, Multi-Center Trial of Microplasmin Intravitreal Injection For Non-Surgical Treatment of Focal Vitreomacular Adhesion (Thrombogenics, MiviTrust)
Principal Investigator 2008-Current The Safety and Efficacy of Al-8309b Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (Alcon, Gate)
Principal Investigator 2009- Current A Phase III, Double-Masked, Multi-Center, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or On An As-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (Genentech, Harbor)
Sub-Principal Investigator 2009-Current A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) (Regeneron, Copernicus)
Principal Investigator 2009-Current Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function (Allergan 031D Retinal Detachment)
Principal Investigator 2009-Current An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (Protocol N)
Principal Investigator 2010-Current SEVEN year observational Update of macular degeneration patients post-MARINA/ANCHOR and HORIZON trials (SEVEN UP STUDY) (Genetech)
Principal Investigator 2010-Current Galley – Genetic Assessment of early to late macular degeneration study(Genetech)
Principal Investigator 2010 Current A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo- Controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration Two Concentrations of FOV2304 (1% and 2%) Twice Daily for the Treatment of Center-involving Clinically Significant Macular Edema Associated with Diabetic Retinopathy (Covance)
Principal Investigator 2010-Current A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (Eli Lilly)
Principal Investigator 2010-Current Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO) (Allergan 001)
Principal Investigator 2010-Current Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System (Allergan 033D)
Principal Investigator 2011-Current A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion (Genentech, SHORE)
Sub-Investigator 2009-Current Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) (Regeneron, COPERNICUS)
Principal Investigator 2011-Current Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy (Allergan, PYRAMID) Investigator-Sponsor Clinical Trials Principal Investigator April 2011-Current Using Optos macine in the Anti-VEGF/OZURDEX Combination Trial (Optos)
Principal Investigator September 2009 -Current OZURDEX as an adjunctive therapy to Anti-VEGF in patients with retinal vein occlusion (RVO)
LICENSURE Texas State Medical License May 18, 1995-Current California State Medical License July 6, 1987-Current Florida State Medical License August 20, 2003-Current Arizona State Medical License September 17, 2003-Current Department of Public Safety – Texas Controlled Substances Certification
GRANT SUPPORT To fund ongoing research, Dr. Singer has received grant support from Optos and compensation in the form of equipment related to the conduct of an investigator-sponsor clinical trial.
|
